FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 744 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative... November 10, 2025 Join the Great American Smokeout for a Healthier Tomorrow November 14, 2023 Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas June 27, 2023 ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 Load more HOT NEWS Shelter Puppies Got A Private Tour Of The Georgia Aquarium Access to Cancer Medicines and Clinical Trials Show Stark Variations Across... Fine Needle Aspiration Biopsy: How to Prepare and What to Expect Coming Soon: Medicare Drug Price Negotiations
